WO2023074813A1 - 光刺激による疾患の治療方法及びそれに用いる装置 - Google Patents
光刺激による疾患の治療方法及びそれに用いる装置 Download PDFInfo
- Publication number
- WO2023074813A1 WO2023074813A1 PCT/JP2022/040211 JP2022040211W WO2023074813A1 WO 2023074813 A1 WO2023074813 A1 WO 2023074813A1 JP 2022040211 W JP2022040211 W JP 2022040211W WO 2023074813 A1 WO2023074813 A1 WO 2023074813A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- light
- light source
- disease
- subject
- nervous system
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 146
- 210000004248 oligodendroglia Anatomy 0.000 claims abstract description 118
- 102000006386 Myelin Proteins Human genes 0.000 claims abstract description 55
- 108010083674 Myelin Proteins Proteins 0.000 claims abstract description 55
- 210000005012 myelin Anatomy 0.000 claims abstract description 55
- 230000004069 differentiation Effects 0.000 claims abstract description 54
- 230000035755 proliferation Effects 0.000 claims abstract description 39
- 230000001678 irradiating effect Effects 0.000 claims abstract description 38
- 230000004083 survival effect Effects 0.000 claims abstract description 38
- 201000010099 disease Diseases 0.000 claims description 74
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 74
- 230000004397 blinking Effects 0.000 claims description 55
- 238000011282 treatment Methods 0.000 claims description 46
- 210000003169 central nervous system Anatomy 0.000 claims description 44
- 230000001737 promoting effect Effects 0.000 claims description 44
- 230000008929 regeneration Effects 0.000 claims description 41
- 238000011069 regeneration method Methods 0.000 claims description 41
- 208000016192 Demyelinating disease Diseases 0.000 claims description 40
- 230000023105 myelination Effects 0.000 claims description 37
- 210000000130 stem cell Anatomy 0.000 claims description 37
- 230000014509 gene expression Effects 0.000 claims description 35
- 230000002265 prevention Effects 0.000 claims description 33
- 230000004770 neurodegeneration Effects 0.000 claims description 30
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 208000015114 central nervous system disease Diseases 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 230000000638 stimulation Effects 0.000 claims description 17
- 201000006417 multiple sclerosis Diseases 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 238000004590 computer program Methods 0.000 claims description 13
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 12
- 101150045217 Mobp gene Proteins 0.000 claims description 11
- 101100347623 Mus musculus Myrf gene Proteins 0.000 claims description 11
- 101100347624 Xenopus laevis myrf gene Proteins 0.000 claims description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims description 10
- 101150077014 sox10 gene Proteins 0.000 claims description 9
- 101100261266 Drosophila melanogaster Trf gene Proteins 0.000 claims description 8
- 101100482145 Mus musculus Tf gene Proteins 0.000 claims description 8
- 101150082690 Pou3f1 gene Proteins 0.000 claims description 8
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 8
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 8
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims description 8
- 208000020431 spinal cord injury Diseases 0.000 claims description 8
- JNLIKIBISICTMS-PEJBKAKVSA-N (e)-but-2-enedioic acid;1-[[4-[(e)-n-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-c-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid Chemical compound OC(=O)\C=C\C(O)=O.CCC1=CC(C(\C)=N\OCC=2C=C(C(C3CCCCC3)=CC=2)C(F)(F)F)=CC=C1CN1CC(C(O)=O)C1.CCC1=CC(C(\C)=N\OCC=2C=C(C(C3CCCCC3)=CC=2)C(F)(F)F)=CC=C1CN1CC(C(O)=O)C1 JNLIKIBISICTMS-PEJBKAKVSA-N 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 7
- 102000003996 Interferon-beta Human genes 0.000 claims description 7
- 108090000467 Interferon-beta Proteins 0.000 claims description 7
- -1 Mbp Proteins 0.000 claims description 7
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 7
- 229960004419 dimethyl fumarate Drugs 0.000 claims description 7
- 230000006806 disease prevention Effects 0.000 claims description 7
- SWZTYAVBMYWFGS-UHFFFAOYSA-N fingolimod hydrochloride Chemical compound Cl.CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 SWZTYAVBMYWFGS-UHFFFAOYSA-N 0.000 claims description 7
- 229960004967 fingolimod hydrochloride Drugs 0.000 claims description 7
- 229960001388 interferon-beta Drugs 0.000 claims description 7
- 229960005027 natalizumab Drugs 0.000 claims description 7
- 229960002450 ofatumumab Drugs 0.000 claims description 7
- 150000003431 steroids Chemical class 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 206010018338 Glioma Diseases 0.000 claims description 6
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 6
- 206010008118 cerebral infarction Diseases 0.000 claims description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 229960003776 glatiramer acetate Drugs 0.000 claims description 6
- 231100000862 numbness Toxicity 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000004452 decreased vision Effects 0.000 claims description 5
- 208000002173 dizziness Diseases 0.000 claims description 5
- 208000013433 lightheadedness Diseases 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 208000002381 Brain Hypoxia Diseases 0.000 claims description 4
- 206010010252 Concentric sclerosis Diseases 0.000 claims description 4
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 4
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 claims description 4
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 4
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 claims description 4
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 4
- 208000021235 Schilder disease Diseases 0.000 claims description 4
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 4
- 201000004810 Vascular dementia Diseases 0.000 claims description 4
- 206010063661 Vascular encephalopathy Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 4
- 208000002670 vitamin B12 deficiency Diseases 0.000 claims description 4
- 206010056332 Panencephalitis Diseases 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 abstract description 10
- 230000036039 immunity Effects 0.000 abstract description 7
- 210000000535 oligodendrocyte precursor cell Anatomy 0.000 abstract description 2
- 210000004556 brain Anatomy 0.000 description 39
- 241000699670 Mus sp. Species 0.000 description 37
- 230000008827 biological function Effects 0.000 description 15
- 230000001276 controlling effect Effects 0.000 description 13
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 12
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 12
- 210000001009 nucleus accumben Anatomy 0.000 description 12
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 10
- 210000002442 prefrontal cortex Anatomy 0.000 description 10
- 102000047918 Myelin Basic Human genes 0.000 description 9
- 101710107068 Myelin basic protein Proteins 0.000 description 9
- 239000011521 glass Substances 0.000 description 9
- 230000035882 stress Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 8
- 101150053137 AIF1 gene Proteins 0.000 description 7
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 7
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 206010012305 Demyelination Diseases 0.000 description 5
- 208000004044 Hypesthesia Diseases 0.000 description 5
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000971 hippocampal effect Effects 0.000 description 5
- 210000001320 hippocampus Anatomy 0.000 description 5
- 208000034783 hypoesthesia Diseases 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 4
- 102100024804 Fibroblast growth factor 22 Human genes 0.000 description 4
- 101001051971 Homo sapiens Fibroblast growth factor 22 Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000003050 axon Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108010041801 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase Proteins 0.000 description 3
- 102100031478 C-type natriuretic peptide Human genes 0.000 description 3
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010060860 Neurological symptom Diseases 0.000 description 3
- 102100038808 Transcription factor SOX-10 Human genes 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000003007 myelin sheath Anatomy 0.000 description 3
- 230000004379 myopia Effects 0.000 description 3
- 208000001491 myopia Diseases 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 2
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000057063 human MAPT Human genes 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 230000036211 photosensitivity Effects 0.000 description 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 208000013449 Visual field disease Diseases 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003037 cerebral aqueduct Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 101150047356 dec-1 gene Proteins 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004313 glare Effects 0.000 description 1
- 229940042385 glatiramer Drugs 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 210000001362 glutamatergic neuron Anatomy 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 229960004461 interferon beta-1a Drugs 0.000 description 1
- 229960003161 interferon beta-1b Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000008437 mitochondrial biogenesis Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 210000002975 pon Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 210000004062 tegmentum mesencephali Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
Definitions
- the present invention relates to a method of treating diseases by optical stimulation and an apparatus used therefor, and more particularly to a method of treating diseases by optical stimulation by irradiating light of a specific wavelength such as violet light at a specific flickering frequency, and an apparatus used therefor. .
- Non-Patent Document 1 exposure to sunlight improves circadian rhythms (Non-Patent Document 1), and light emitted from LED lighting and liquid crystal displays that use LEDs as backlights has a significant effect on the body and mind (Non-Patent Document 1). 2) It has been reported that violet light prevents myopia and suppresses the onset of myopia (Patent Document 1). Particularly recently, the present inventors have made interesting reports about the effects of violet light on the eyes. It has been proposed that the myopia population is still increasing worldwide, and there are great expectations in recent years.
- Diseases to be treated include, for example, demyelinating diseases, neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease and spinal cord injury, tumors such as brain tumors (glioma), and cerebral infarction. including central nervous system diseases.
- demyelinating diseases include, for example, demyelinating diseases, neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease and spinal cord injury, tumors such as brain tumors (glioma), and cerebral infarction. including central nervous system diseases.
- ALS amyotrophic lateral sclerosis
- glioma brain tumors
- cerebral infarction including central nervous system diseases.
- Demyelinating disease refers to a disease caused by degeneration and loss of the myelin sheath of nerve fibers.
- An example of a demyelinating disease is multiple sclerosis (MS).
- MS multiple sclerosis
- Multiple sclerosis is a chronic inflammatory disease of the central nervous system characterized by damage to myelin, dysfunction of the brain, optic nerve and spinal cord.
- Oligodendrocytes are known to be associated with various diseases.
- Non-Patent Document 4 shows that oligodendrocytes decrease with aging.
- Non-Patent Document 5 shows that oligodendrocytes decrease in Alzheimer's disease.
- Non-Patent Document 6 shows that differentiation of oligodendrocytes is important for recovery from cerebral infarction.
- Non-Patent Document 7 shows that oligodendrocyte differentiation is important for recovery from spinal cord injury.
- Fibroblast growth factor 21 is a pleiotropic hormone considered to be a key regulator of energy homeostasis. FGF21 is mainly secreted from the liver, but it is known that it may also be expressed in skeletal muscle. FGF21 signaling to hypothalamic glutamatergic neurons is known to be required to induce a decrease in sugar intake and alter sweet taste preferences in mice. Other studies have shown that FGF21 activates PGC-1 ⁇ and enhances mitochondrial efficacy in human dopaminergic neurons, suggesting that FGF21 may play a role in dopaminergic neuron viability and PD. suggests there is.
- POC-1 ⁇ peroxisome proliferator-activated receptor gamma coactivator-1 ⁇
- the present inventors have found that irradiation with light of a specific wavelength, particularly violet light (visible light in the 360-400 nm region) at a blinking frequency promotes the survival, proliferation and differentiation of oligodendrocyte progenitor cells and oligodendrocytes, It was found that it promotes regeneration and increase of myelin, activates nerves, and activates immunity.
- the present invention is based on such findings, and its purpose is to irradiate demyelinating diseases, neurodegenerative diseases, tumors, and central nervous system by irradiating light of a specific wavelength such as violet light at a constant light or a specific blinking frequency.
- An object of the present invention is to provide a method for treating and/or preventing diseases such as neurological diseases and symptoms associated with myelination, as well as devices and programs used therefor.
- the present invention provides methods for promoting the regeneration or increase of myelin in at least one region of the central nervous system and the survival, proliferation of oligodendrocyte progenitor cells or oligodendrocytes in at least one region of the central nervous system.
- another object is to provide a method for promoting differentiation.
- the present disclosure provides a method for treating and/or preventing disease in a subject in need of treatment and/or prevention, the method comprising irradiating the subject with a specific wavelength of light.
- said disease is selected from the group consisting of demyelinating diseases, neurodegenerative diseases, tumors, central nervous system diseases and conditions associated with myelination.
- a method according to the present disclosure comprises irradiating a subject with light of a specific wavelength to promote regeneration or increase of myelin in at least one region of the central nervous system of the subject to treat and/or prevent disease in the subject. and said disease is selected from the group consisting of demyelinating diseases, neurodegenerative diseases, tumors, central nervous system diseases and conditions associated with myelination.
- the present disclosure provides a method for treating and/or preventing a disease in a subject in need of treatment and/or prevention, the method comprising controlling a light irradiation device to treating and/or preventing a disease in a subject by irradiating the subject with light of a wavelength to thereby promote regeneration or increase of myelin in at least one region of the central nervous system of the subject, wherein the disease is , demyelinating diseases, neurodegenerative diseases, tumors, central nervous system diseases and conditions associated with myelination.
- the light irradiation device includes a light source that irradiates a living body with light of a specific wavelength at a constant light or at a specific blinking frequency, and a controller that controls the blinking frequency of the light source.
- demyelinating diseases include multiple sclerosis, neuromyelitis optica (Devic syndrome), concentric sclerosis (Balo disease), acute disseminated encephalomyelitis (ADEM), inflammatory diffuse sclerosis (Schilder's disease). disease), subacute sclerosing panencephalitis (SSPE), progressive multifocal leukoencephalopathy (PML), hypoxic encephalopathy, central pontine myelination, vitamin B12 deficiency, Guillain-Barré syndrome and Binswanger disease is not limited to
- neurodegenerative diseases include, but are not limited to amyotrophic lateral sclerosis (ALS), Alzheimer's disease and spinal cord injury.
- ALS amyotrophic lateral sclerosis
- Alzheimer's disease spinal cord injury.
- tumors include, but are not limited to, brain tumors (gliomas).
- central nervous system diseases include, but are not limited to, stroke.
- symptoms associated with myelination include, but are not limited to, pain, numbness, urinary leakage, light-headedness, decreased vision and fatigue.
- the present disclosure provides a method for promoting myelin regeneration or increase in at least one region of the central nervous system in a subject in need of treatment and/or prevention, the method comprising: irradiating a subject with light of a specific wavelength to promote regeneration or increase of myelin in at least one region of the central nervous system of the subject.
- the present disclosure promotes survival, proliferation or differentiation of oligodendrocyte progenitor cells or oligodendrocytes in at least one region of the central nervous system in a subject in need of treatment and/or prevention.
- a method for irradiating a subject with light of a specific wavelength to promote survival, proliferation or differentiation of oligodendrocyte progenitor cells or oligodendrocytes in at least one region of the central nervous system of the subject for a method comprising:
- subjects consist of steroids, glatiramer acetate, fingolimod hydrochloride, siponimod fumarate, dimethyl fumarate, interferon beta (interferon beta-1a or interferon beta-1b), natalizumab, and ofatumumab.
- the patient may be receiving or has received at least one drug selected from the group.
- the method of the present disclosure comprises: It can be applied to patients.
- the light used is violet light.
- the specific wavelengths used include 350-400 nm, particularly about 380 nm.
- the flashing frequency used is 0 Hz or 30-70 Hz, particularly 0 Hz or 35-60 Hz, more particularly 0 Hz or about 40 Hz.
- the irradiation conditions further include the irradiation time of the light source.
- the light source may be spectacles with a light source or a spectacle frame, a desktop light source, a mobile terminal-mounted light source, a light source installed in front of or near the face, a portable light source, an indoor lighting, or a table lamp.
- the subject to which the method of the present disclosure is applied is human.
- the present disclosure includes at least one light source that emits light, and a drive circuit that drives the light source, and the light emitted by the light source is irradiated to a living body to treat a disease and/or
- the device is selected from the group consisting of symptoms that
- the present disclosure includes at least one light source that emits light, and a drive circuit that drives the light source, and the light emitted by the light source is applied to a living body to regenerate or regenerate myelin.
- the present invention relates to a device for promoting myelin regeneration or increase by photostimulation, which is light of a specific wavelength that produces an increase-promoting effect.
- the present disclosure includes at least one light source that emits light, and a drive circuit that drives the light source, wherein the light emitted by the light source irradiates a living body to oligodendrocyte progenitor cells.
- the present invention relates to a device for promoting survival, proliferation or differentiation of oligodendrocyte progenitor cells or oligodendrocytes by photostimulation, which is light of a specific wavelength that produces an effect of promoting survival, proliferation or differentiation of cells or oligodendrocytes.
- a device of the present disclosure comprises a drive circuit comprising: at least one processor communicatively coupled to the light source and at least one memory; including memory.
- the present disclosure is a method of operating a device according to the present disclosure, wherein the device comprises a light source that irradiates a living body with light of a specific wavelength at a constant light or a specific blinking frequency, and a blinking frequency of the light source.
- the control unit controls the blinking frequency of the light source in the range of 0 Hz or 30 to 75 Hz, and the light source irradiates the living body with light having a wavelength in the range of 350 to 400 nm. It relates to a method of operation, including steps.
- the present disclosure provides a device comprising a light source that irradiates a living body with light of a specific wavelength at a constant light or a specific blinking frequency, and a control unit that controls the blinking frequency of the light source. It relates to a computer program for carrying out an operating method.
- the survival, proliferation, or differentiation of oligodendrocyte progenitor cells or oligodendrocytes in a living body exposed to light can be promoted, and the regeneration or increase of myelin can be promoted. Promoting the regeneration or increase of myelin leads to the treatment and/or prevention of diseases such as demyelinating diseases, neurodegenerative diseases, tumors, central nervous system diseases, and conditions associated with myelination.
- the light is violet light, for example.
- the living body can be irradiated with violet light having a wavelength outside the visible light range, so that the living body can be affected without feeling the flicker or glare of white light.
- Violet light is light with a wavelength of 360 to 400 nm, which has lower visual sensitivity than white light and is in a wavelength range that does not or does not give discomfort to living organisms (especially humans).
- light with a wavelength in the range of 350-400 nm such as light with a wavelength of any of 350 nm, 360 nm, 370 nm, 380 nm, 390 nm or 400 nm, or defined by any wavelength above Any wavelength of light within the range (eg, 370-390 nm range) may be used.
- the wavelength includes approximately 380 nm.
- the term "about” means including 5% before and after the numerical value modified by this term.
- the light irradiation state is constant light (that is, 0 Hz) or a blinking frequency of over 0 Hz to 150 Hz.
- the blinking frequency is approximately 40 Hz.
- the light is, for example, irradiance in the range of 0.5 to 1000 ⁇ W/cm 2 , or 0.1 ⁇ W/cm 2 (0.001 W/m 2 ) to 5000 ⁇ W/cm 2 (50 W/cm 2 ). m 2 ).
- violet light or the like can be irradiated within the above irradiance range to affect oligodendrocytes. In particular, it has been confirmed that even a very small amount of weak light (light with low photosensitivity) can cause a characteristic phenomenon.
- the control unit of the apparatus controls the irradiation state of the light (including constant light or blinking frequency), irradiance, irradiation time, It can be executed by changing irradiation conditions such as irradiation start time, irradiation end time, constant light or flashing frequency.
- the various irradiation conditions described above are controlled in isolation so that irradiation conditions suitable for producing control of oligodendrocytes can be arbitrarily set to achieve the desired effect. .
- the light source may be glasses with a light source (see, for example, FIG. 2) or a light source installed in front of or near the face, such as a glasses frame, a desktop light source, or a mobile terminal-mounted light source.
- a light source installed in front of or near the face, such as spectacles with a light source or a spectacle frame that is easy to wear and does not cause discomfort on a daily basis. You can always irradiate even in difficult scenes and environments.
- the light source may be a non-installed light source such as a portable light source, or an installed light source such as a room light, table lamp, or dedicated device.
- the device can have various light source forms depending on the usage environment.
- the light source may be used in combination with glasses, spectacle lenses, or contact lenses that allow violet light to pass through.
- sunlight passing through glasses, spectacle lenses, or contact lenses that allow violet light to pass through may be used as a light source.
- the method by photostimulation according to the present disclosure is a method of controlling oligodendrocytes by irradiating a living body (e.g., mammals including humans) with light of a specific wavelength at a constant light or a specific flickering frequency, It is characterized by controlling the emission of light that controls the gene expression of oligodendrocytes of the living body that has received the light.
- a living body e.g., mammals including humans
- a device is a device for treating or preventing a disease by irradiating a living body with constant violet light, comprising: a light source emitting the violet light; and a light emission time control unit for emitting light for a period of time, wherein the disease is selected from the group consisting of demyelinating diseases, neurodegenerative diseases, tumors, central nervous system diseases, and symptoms associated with myelination.
- methods for treating and/or preventing said disease in a subject in need thereof treatment and/or methods for promoting regeneration or increase of myelin in at least one region of the central nervous system in a subject in need of prevention, treatment and/or prevention of at least one area of the central nervous system.
- FIG. 4 is a graph showing the relationship between spectral irradiance and wavelength of light from a violet fluorescent lamp. The optical spectrum of an LED with a peak wavelength of 375 nm.
- 1 is a block diagram of one embodiment of a biological function control device according to the present invention; FIG. Boxplots showing genes related to myelination and oligodendrocyte differentiation among the genes whose expression is upregulated by violet light (VL). WL: white light, VL: violet light.
- FIG. 2 shows expression patterns of oligodendrocyte differentiation marker molecules.
- OPC oligodendrocyte precursor cell
- pre-OL pre-oligodendrocyte
- OL mature oligodendrocyte.
- FIG. 2 shows sections of brain cortex from experimental group mice (VL) and control group mice (WL).
- Fig. 10 is a graph comparing the MBP-expressing regions of experimental group mice (VL) and control group mice (WL).
- Fig. 3 is a graph confirming the gene expression of oligodendrocyte biomarkers SOX10, CNP, MAG, MBP, Mobp and Myrf in brain hippocampal tissue by quantitative PCR.
- Fig. 1 oligodendrocyte precursor cell
- pre-OL pre-oligodendrocyte
- OL mature oligodendrocyte.
- FIG. 3 is a photograph showing the expression of c-Fos, MBP, CC1 and Iba1 in the brain Nucleus Accumbens.
- FIG. 2 is a diagram showing the Nucleus Accumbens (nucleus accumbens) region of the brain.
- Nucleus Accumbens depression was induced in the experimental group (cVL)
- FIG. 10 is a graph versus no control group (WL). Fig.
- FIG. 3 is a photograph showing the expression of c-Fos, MBP, CC1 and Iba1 in the prefrontal cortex of the brain.
- FIG. 2 is a diagram showing regions of the Prefrontal cortex of the brain.
- depression was induced in the experimental group (cVL)
- depression was induced in the control group (WL)
- depression was induced.
- FIG. 10 is a graph versus no control group (WL).
- the depression-induced experimental group (cVL) was compared with the depression-induced control group (WL) and the non-depression-induced control group (WL).
- FIG. 3 is a graph comparing the expression of FGF21 mRNA in the hippocampus of the left brain and right brain between the experimental group (VL) and the control group (WL). left indicates the left brain and right indicates the right brain.
- 4 is a graph comparing MAG expression (40 Hz VL) in Alzheimer's disease model animals of P301S mutant human tau transgenic mice (PS19) irradiated with 40 Hz violet light and in a control group (cWL).
- a device, a method of operating the device, and a computer program for carrying out the method of operation will be described with reference to the drawings. The present invention is not limited to the following embodiments and examples, and includes various modifications and applications within the scope of the present invention.
- a method for treating and/or preventing a disease according to the present disclosure is characterized by irradiating a subject in need of treatment and/or prevention with light of a specific wavelength.
- one aspect of the present disclosure is to promote survival, proliferation or differentiation of oligodendrocyte progenitor cells or oligodendrocytes in at least one region of the central nervous system in a subject in need of treatment and/or prevention.
- the subject is irradiated with light of a specific wavelength to promote survival, proliferation or differentiation of oligodendrocyte progenitor cells or oligodendrocytes in at least one region of the central nervous system of the subject.
- the subject is an organism having oligodendrocytes, such as a mammal, and in particular can be a human.
- Oligodendrocytes are one of the glial cells in the central nervous system and are also called oligodendrocytes.
- the cells that make up the central nervous system include nerve cells that transmit electrical signals to exchange information, and glial cells that support nerve cells by providing nutrients.
- Oligodendrocytes, which are classified as glial cells, are particularly responsible for the formation of myelin (myelin sheath) that covers the axonal portion of nerve cells. Oligodendrocytes undergo a series of steps of proliferation, migration, differentiation, myelination, and finally myelinate axons.
- Myelin acts as an insulator, speeding up the transmission of electrical signals and preventing them from leaking out of the axon and mixing with information carried by other axons.
- Demyelinating disease is an intractable disease of unknown cause, in which the myelin that covers nerves disappears (demyelination) and nerve signals cannot be transmitted properly, resulting in various neurological symptoms such as numbness in the extremities. Suppressing demyelination and promoting remyelination are the keys to the treatment of demyelinating diseases. Oligodendrocytes are known to be associated with various diseases.
- oligodendrocytes decrease with aging, and it is known that oligodendrocytes decrease in Alzheimer's disease. It is known that oligodendrocyte differentiation is important for recovery from cerebral infarction, and oligodendrocyte differentiation is known to be important for recovery from spinal cord injury.
- at least one region of the central nervous system e.g. , mesencephalon, cerebral peduncle, pretectal region, cerebral aqueduct, pons, cerebellum, medulla oblongata, spinal cord, but not limited to these.
- one aspect of the present disclosure is to irradiate a subject with light of a specific wavelength to irradiate Sox10, Cnp, Mag, Mbp, Mobp, Myrf, Pou3f1 and Trf in at least one region of the central nervous system of a subject. It also relates to a method of increasing expression of at least one gene selected from the group.
- one aspect of the present disclosure is a method for promoting myelin regeneration or increase in at least one region of the central nervous system in a subject in need of treatment and/or prevention, the method comprising: A method comprising irradiating a subject with light of a specific wavelength to promote regeneration or increase of myelin in at least one region of the subject's central nervous system.
- the subject is a myelin-bearing organism, such as a mammal, and may in particular be a human.
- Regeneration or increase of myelin in a subject can be evaluated, for example, by visualizing myelin by MRI using a technique called the myelin map method (for example, Fujiyoshi et al., J Neurosci. 2016 Mar 2;36 (9):2796-808.).
- the myelin map method MRI (3 Tesla (3T) device) can be used to image myelin in about 10 minutes, and remyelination can be easily visualized.
- one aspect of the present disclosure is a method for treating and/or preventing a disease in a subject in need of such treatment and/or prevention, the method comprising exposing the subject to a specific wavelength of light. and wherein said disease is selected from the group consisting of demyelinating diseases, neurodegenerative diseases, tumors, central nervous system diseases and conditions associated with myelination. and the method includes irradiating the subject with light of a specific wavelength to promote regeneration or increase of myelin in at least one region of the central nervous system of the subject to treat and/or prevent the disease in the subject.
- the method includes irradiating the subject with light of a specific wavelength to promote regeneration or increase of myelin in at least one region of the central nervous system of the subject to treat and/or prevent the disease in the subject.
- Demyelinating diseases include, for example, multiple sclerosis, neuromyelitis optica (Devic syndrome), concentric sclerosis (Balo disease), acute disseminated encephalomyelitis (ADEM), inflammatory diffuse sclerosis (Schilder disease), Acute sclerosing panencephalitis (SSPE), progressive multifocal leukoencephalopathy (PML), hypoxic encephalopathy, central pontine myelination, vitamin B12 deficiency, Guillain-Barré syndrome and Binswanger disease, which is not limited to
- Multiple sclerosis is a demyelinating disease of the central nervous system, a chronic inflammatory disease characterized by myelin damage and dysfunction of the brain, optic nerve, and spinal cord. The exact cause of multiple sclerosis is not known. When multiple sclerosis occurs, the body's own immune system attacks the myelin sheath, resulting in 'demyelination' in which the axons become bare. When demyelination occurs, nerve conduction becomes impaired and neurological symptoms appear. Major symptoms include visual field disorder, diplopia, sensory disorder, movement disorder, gait disorder, dysuria, dysarthria, and higher brain dysfunction. Multiple sclerosis (MS) is divided into four major types: relapsing remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), and progressive relapsing MS (PRMS). can be separated.
- RRMS relapsing remitting MS
- SPMS secondary progressive MS
- PPMS primary progressive MS
- PRMS progressive
- methylprednisolone and plasma exchange therapy are often used as acute short-term therapy. Although these treatments are effective in the short term, multiple sclerosis is a chronic disease with persistent disease activity, so treatment methods aimed at improving long-term prognosis are in greater demand. ing.
- therapeutic agents in addition to steroids such as methylprednisolone, glatiramer acetate, fingolimod hydrochloride, siponimod fumarate, dimethyl fumarate, interferon beta, natalizumab, and ofatumumab can be used.
- the subject is at least one selected from the group consisting of steroids, glatiramer acetate, fingolimod hydrochloride, siponimod fumarate, dimethyl fumarate, interferon beta, natalizumab, and ofatumumab.
- the patient may be taking or has taken one drug. Diseases can be more effectively controlled by a combination therapy of administration of these agents and light stimulation according to the present invention.
- one aspect of the present disclosure is a method for treating and/or preventing a demyelinating disease in a subject in need thereof, the method comprising irradiating the subject with a specific wavelength of light.
- At least one agent selected from the group consisting of steroids, glatiramer acetate, fingolimod hydrochloride, siponimod fumarate, dimethyl fumarate, interferon beta, natalizumab, and ofatumumab. also related to
- a neurodegenerative disease can be, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, or spinal cord injury, but is not limited to these.
- ALS amyotrophic lateral sclerosis
- Alzheimer's disease or spinal cord injury, but is not limited to these.
- a tumor can be, for example, a brain tumor (glioma), but is not limited to this.
- a central nervous system disease can be, for example, cerebral infarction, but is not limited to this.
- Symptoms associated with myelination can include, but are not limited to, pain, numbness, urine leakage, lightheadedness, decreased vision, and fatigue.
- the light used can be violet light.
- the specific wavelength used can include 350-400 nm, and particularly about 380 nm.
- the blinking frequency can be, for example, 0 Hz or 30-70 Hz, in particular 0 Hz or 35-60 Hz.
- the blinking frequency can especially be 0 Hz or about 40 Hz.
- the irradiation conditions may further include the irradiation time of the light source.
- the light source can be, but is not limited to, spectacles or spectacle frames with a light source, desktop light source, mobile terminal mounted light source, front or near face light source, portable light source, room lighting, or table lamp.
- the specific time of light irradiation is any time in the range of 10 seconds to 24 hours per day, e.g., 10 seconds, 30 seconds, 45 seconds, 1 minute, 3 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, It can be any time of 12 hours, 18 hours, 24 hours, or any time within the range defined by any of the above (eg, 1 to 12 hours).
- the specific period of continued light irradiation is, for example, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 6 months, It can be for a period of 1 year, 2 years, 3 years or more.
- One aspect of the present disclosure is a method for treating and/or preventing a disease in a subject in need of treatment and/or prevention, the method comprising controlling a light irradiation device to emit light of a specific wavelength to treat and/or prevent a disease in the subject, wherein the disease is demyelination A method selected from the group consisting of diseases, neurodegenerative diseases, tumors, central nervous system diseases and conditions associated with myelination.
- the light emitting device can emit violet light.
- the light irradiation device can irradiate light with a wavelength of 350-400 nm, particularly light with a wavelength of about 380 nm.
- the light irradiation device may be controllable with a blinking frequency of eg 0 Hz or 30-70 Hz, especially 0 Hz or 35-60 Hz, and the blinking frequency can be especially 0 Hz or about 40 Hz.
- the light irradiation device may be one capable of controlling the irradiation time.
- the form of the light source can be, but is not limited to, spectacles or spectacle frames with a light source, desktop light source, mobile terminal mounted light source, front or near face light source, portable light source, indoor lighting, or table lamp.
- the disease treatment and/or prevention device may include at least one light source that emits light and a driving circuit that drives the light source.
- the light emitted by the light source is light of a specific wavelength that produces therapeutic and/or preventive effects for diseases by irradiating the living body.
- a device for promoting myelin regeneration or increase by photostimulation can include at least one light source that emits light and a drive circuit that drives the light source.
- the light emitted by the light source is light of a specific wavelength that promotes the regeneration or increase of myelin by irradiating the living body.
- a device for promoting survival, proliferation or differentiation of oligodendrocyte progenitor cells or oligodendrocytes comprises at least one light source that emits light and a drive circuit that drives the light source.
- the light emitted by the light source is light of a specific wavelength that promotes the survival, proliferation, or differentiation of oligodendrocyte progenitor cells or oligodendrocytes when irradiated to a living body.
- a device for treating and/or preventing the aforementioned diseases by light stimulation a device for promoting myelin regeneration or increase by light stimulation, survival, proliferation or differentiation of oligodendrocyte progenitor cells or oligodendrocytes by light stimulation may be generically referred to as a "biofunction control device” or simply as a “device”.
- these devices can stimulate oligodendrocyte progenitor cells or oligodendrocytes in the body, activate nerves, and activate immunity.
- oligodendrocyte progenitor cells or oligodendrocytes are enhanced in specific gene expression to promote survival, proliferation or differentiation, resulting in promotion of regeneration or increase of myelin, Furthermore, the result leads to the treatment and/or prevention of said diseases.
- the apparatus irradiates a living body with violet light at constant light or at a specific flickering frequency to promote the survival, proliferation, or differentiation of oligodendrocyte progenitor cells or oligodendrocytes.
- a device for controlling biological functions such as myelination, activating nerves, activating immunity, and treating or preventing diseases, comprising: a light source that emits the violet light; A luminescence cycle control unit that controls the light or a specific flickering frequency, and a luminescence time control unit that irradiates the violet light for a specific time or for a specific period, and controls the biological function to treat and/or prevent disease.
- the disease is selected from the group consisting of demyelinating diseases, neurodegenerative diseases, tumors, central nervous system diseases and conditions associated with myelination.
- the device according to the present disclosure is a device for irradiating a living body with constant light of violet light to control the biological function, comprising: a light source emitting the violet light; and a light emission time control unit that irradiates for a specific time or for a specific period.
- the device according to the present disclosure includes at least one light source that emits light and a driving circuit that drives the light source, and the light emitted by the light source is applied to a living body. It relates to a device used to control said biological function and treat and/or prevent said disease by means of photo-stimulation, which is light of a specific wavelength that produces said effect. Accordingly, one aspect of the present disclosure includes at least one light source that emits light, and drive circuitry that drives the light source, the drive circuitry communicatively coupled to the light source and at least one memory.
- At least one processor and at least one memory for storing processor-executable instructions, wherein the light source emits light of a specific wavelength that causes treatment and/or prevention of the disease by irradiating a living body. It relates to a device for treatment and/or prevention of said diseases by means of photo-stimulation, which device is adapted to emit light. Also, one aspect of the present disclosure includes at least one light source that emits light and a driving circuit that drives the light source, the driving circuit being communicatively connected to the light source and at least one memory. At least one processor and at least one memory for storing processor-executable instructions, wherein the light source emits light of a specific wavelength that irradiates a living body to produce an effect that promotes myelin regeneration or growth.
- one aspect of the present disclosure includes at least one light source that emits light, and a drive circuit that drives the light source, the drive circuit communicatively connected to the light source and at least one memory. comprising at least one processor and at least one memory for storing instructions executable by the processor, wherein the light source irradiates a living body to promote survival, proliferation or differentiation of oligodendrocyte progenitor cells or oligodendrocytes.
- the wavelength of light emitted by the light source is not particularly limited, but violet light defined as 360-400 nm is used in some embodiments.
- the oscillation frequency can preferably be applied to a light source that can range from 0 (normal light, DC light) to 150 Hz.
- the frequency can be adjusted in units of 0.5 Hz or 1 Hz by setting the control section, and light with any flickering frequency can be generated.
- Increasing the blinking frequency also has the advantage that the blinking becomes less annoying, although there are individual differences.
- the blinking frequency is not limited to 10 Hz or 60 Hz used in the experimental examples.
- the irradiance from the light source may be variable or constant.
- a maximum power of 310 ⁇ W/cm 2 is used.
- a light source with such irradiance can be easily applied to spectacles or spectacle frames, or other portable illumination devices, so that they can be worn in daily life.
- a very small amount of weak light light with low photosensitivity
- causes a characteristic phenomenon. can be expected.
- the light may be specified by relative luminosity. Since the features of the present invention can be realized even with a low relative luminous efficiency, it is possible to irradiate a blinking violet light that causes stimulation to the living body under the low relative luminous efficiency, and to stimulate a desired part without burdening the living body. can be done.
- the light irradiation time is preferably set arbitrarily according to the purpose, and may be short or long.
- the light can optionally be intermittent (regular or irregular) or continuous.
- the light irradiation time can be set, for example, between 8:00 am and 1:00 pm, between 9:00 am and 12:00 am, or between 10:00 am and 11:00 am. can be at least 10 minutes, at least 15 minutes, at least 20 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, or 5 hours. In some embodiments, 3 hours of irradiation between 9:00 am and 12:00 am or 2 hours of irradiation between 9:00 am and 11:00 am is applied.
- a timer function can be used for such irradiation with a set time.
- the light source can be spectacles with a light source or a spectacle frame. Such spectacles or spectacle frames are easy to wear and have a light source that emits a blinking frequency attached to the spectacles or spectacle frames that do not cause discomfort on a daily basis.
- the light source may be a light source installed in front of or near the face, such as a desk light source or a light source attached to a mobile terminal, or a non-installed light source such as a portable light source, or an indoor lighting, a desk stand, a dedicated device, or the like.
- the light source may be an installation type light source, and the device may have various light source forms according to the usage environment.
- the control unit is a part that controls the irradiation state of light from the light source (normal light or flashing frequency).
- the controller may include a power source for powering the light source, such power source may be a battery or routed by cable to a battery mounted in another location. good too. Moreover, when it does not move in one place, the form connected to a household power supply etc. may be sufficient.
- the control unit changes the irradiation conditions such as the blinking frequency of the light, the irradiance, the irradiation time, the irradiation start time, the irradiation end time, the blinking frequency, etc. is preferred. Since such a control unit isolates and controls the various irradiation conditions described above, it is possible to arbitrarily set irradiation conditions suitable for producing desired biological function control and obtain desired effects.
- control unit may have a light source controller and a timer function.
- the controller can include functions such as changing the frequency and irradiance and setting the irradiation time.
- timer function can be exemplified by one that can set the irradiance time of light. Such a controller and timer function may be provided integrally with the instrument, or may be provided as separate members.
- FIG. 5 shows a block diagram of a simplified example of a device that can be used for the above-described biological function control and the like.
- the devices shown in FIG. It can include various functions of a device that promotes survival, proliferation or differentiation of oligodendrocytes (these can be collectively referred to simply as a “biological function control device”), and is therefore described above in this specification. All devices can be represented by the block diagram of FIG.
- a biological function control device can have a light source 10 and a control unit 20 .
- a light source 10 emits light of a specific wavelength.
- the wavelength of the light emitted by the light source 10 preferably includes VL or 350 to 400 nm, and more preferably includes 380 nm.
- the light source 10 may be any light source, and a light emitting diode (LED) can be preferably used from the viewpoint of small size, long life, and ease of blinking control (an example of the spectrum of a violet fluorescent lamp is shown in FIG. 3, LED (see Fig. 4 for an example of the spectrum of ).
- the number of light sources 10 may be one or more depending on the target irradiation intensity and irradiation range of the light sources.
- the control unit 20 is wired or wirelessly connected to the light source 10 and configured to control the irradiation conditions of the light source 10 .
- the irradiation conditions can include at least one of the blinking frequency and the irradiation time of the light source 10, and therefore the control unit 20 can include at least one of the blinking frequency control unit 20a and the irradiation time control unit 20b.
- the blinking frequency may preferably be 0 Hz or 30-75 Hz, more preferably 0 Hz or 35-45 Hz, particularly preferably 0 Hz or 40 Hz. Note that the blinking frequency of 0 Hz means constant lighting.
- the irradiation time can be arbitrarily determined, for example, in the range of 10 seconds to 24 hours per day, and the specific period of continuation of irradiation can also be arbitrarily determined, for example, from one day to several years or longer. .
- the control unit 20 can include a processor such as a CPU (Central Processing Unit), and executes processing for controlling the irradiation conditions of the light source 10.
- the processing performed by the control unit 20 may be realized by a computer program, or may be realized by hardware based on logic circuits.
- the computer program may be stored on a computer-readable recording medium.
- a recording medium storing a computer program may be a non-transitory recording medium.
- the non-transitory recording medium is not particularly limited, and may be, for example, a memory card, CD-ROM, or other recording medium.
- a computer program stored in a recording medium can be implemented in a computer unit via an appropriate reader. Appropriate readers include, for example, a card reader when the recording medium is a memory card, and a CD drive when the recording medium is a CD-ROM.
- the computer program may be downloaded from an external server to the computer unit via a communication network.
- the driving circuitry includes at least one processor communicatively connected to the light source and at least one memory, and at least one memory for storing instructions executable by the processor. Possible.
- the light source 10 of the biological function control device shown in FIG. 5 is spectacles with a light source or a spectacle frame, a desktop light source, a light source attached to a mobile terminal, a light source installed in front of or near the face, a portable light source, an indoor lighting, or a tabletop stand. good.
- the biological function control device includes glasses or a glasses frame on which at least the light source 10 out of the light source 10 and the control unit 20 is attached, a desk light, a mobile terminal, a mobile terminal case, head-mounted items (cap, earphone headphones, etc.), portable lights, room lights, or lighted products, including table lamps.
- the apparatus for controlling biological functions by optical stimulation irradiates a living body with light of a specific wavelength such as violet light at a constant light or a specific flickering frequency to treat and/or prevent the disease.
- a specific wavelength such as violet light at a constant light or a specific flickering frequency
- myelin regeneration or expansion can lead to promotion of myelin regeneration or expansion, as well as promotion of survival, proliferation or differentiation of oligodendrocyte progenitor cells or oligodendrocytes.
- one aspect of the present invention relates to a method for operating a biological function control device using optical stimulation.
- some embodiments of the present disclosure are a method of operating a device for use in controlling biological functions, wherein the device comprises a light source that irradiates a living body with light of a specific wavelength at constant light or at a specific flickering frequency. and a controller for controlling the flickering frequency of the light source, wherein the device irradiates a living body with light of a specific wavelength in a normal light or at a specific flickering frequency.
- the blinking frequency of the light source may be controlled in the range of 0 Hz or 30 to 75 Hz, and the light source may irradiate the living body with light having a wavelength in the range of 350 to 400 nm.
- one aspect of the present invention provides a device comprising a light source that irradiates a living body with light of a specific wavelength at a constant light or a specific blinking frequency, and a controller that controls the blinking frequency of the light source. It also relates to a computer program for carrying out the method.
- the computer program according to the present disclosure may be stored in a non-transitory computer-readable medium.
- a computer program according to the present disclosure is capable of performing predetermined steps when instructions are executed by a processor.
- one aspect of the present disclosure is a non-transitory computer-readable medium having instructions stored thereon that, when executed by a processor, emit light of a particular wavelength at all times or at a particular frequency.
- a device comprising a light source that irradiates a living body with a flickering frequency and a control unit that controls the flickering frequency of the light source, wherein the control unit controls the flickering frequency of the light source within a range of 0 Hz or 30 to 75 Hz. and operating the device such that the light source irradiates a living body with light of a wavelength in the range of 350-400 nm.
- one aspect of the present invention relates to a device for treating and/or preventing the disease by light stimulation
- the device may include glasses, spectacle lenses, or contact lenses that allow violet light to pass through.
- Such devices can be used to favorably influence biological functions such as survival, proliferation or differentiation of oligodendrocyte progenitor cells or oligodendrocytes, myelination, neural activation and immune activation.
- the use of such devices may allow treatment and/or prevention of said diseases.
- Example 1 Light irradiation to mouse
- Mouse cages were placed in a light exposure apparatus (New Opt, Kanagawa, Japan) fitted with LEDs (white: NF2W757GT-F1, purple: NSSU123, Nichia Corporation, Tokushima) on top of the box.
- Mice in the control group were housed under white light (WL) from 8:00 am to 8:00 pm with a 12 hour light/12 hour dark cycle.
- Experimental groups of mice were also exposed to white light under the same conditions, except for exposure to violet light (VL). In the experimental group, mice were exposed to violet light daily from 10 am to 12 am for 16 weeks.
- Violet light used light with a wavelength of 360 to 400 nm (peak wavelength of 375 nm), and the irradiance was within the range of 0.5 to 1000 ⁇ W/cm 2 , and the illumination was at normal light (blinking frequency of 0 Hz).
- tissue preparation After 16 weeks of light irradiation, 85-week old mice were sacrificed by cervical dislocation and the whole brain of each mouse was collected. The tissue was divided in half, half used for immunostaining and the other half used for gene expression analysis. All tissues were snap frozen in liquid nitrogen and stored at -80°C until analysis.
- RNA extraction Hippocampal tissue was homogenized with QIAzol lysis reagent (Qiagen, Germany) and total RNA was extracted using the RNeasy mini kit (Qiagen, Germany). The quality and quantity of all RNA samples were determined using the Nanodrop RNA Nano kit (2100 Agilent Bioanalyzer Technologies, CA, USA). Only samples with a RIN (RNA integrity number) greater than 8.0 were used for gene expression analysis.
- Ct cycle thresholds
- RNA-seq analysis was performed on the hippocampus after exposure of aged mice to VL.
- 404 DEGs (differentially expressed genes) were identified, including 231 up-regulated and 173 down-regulated genes.
- Gene ontology (GO) analysis was performed to classify DEGs into upregulated and downregulated genes, showing that VL stimulation was associated with neural circuit formation, including neuronal envelopment, axonal encapsulation, and myelination. It was found to increase the expression of the genes involved.
- glial cell development is included in the cluster of upregulated genes.
- aged mice exposed to VL show upregulation of genes associated with oligodendrocyte differentiation.
- genes upregulated by VL play important roles in the differentiation of pre-oligodendrocytes (pre-OL) to mature oligodendrocytes, including Sox10, Cnp, Mag, It contains genes involved in myelin maturation such as Mbp, Mobp ( Figures 6 and 7).
- VL increased the expression of Myrf, a known Sox10 cofactor that induces oligodendrocyte differentiation genes.
- VL also induces other oligodendrocyte-associated genes such as Pou3f1 and transferrin (Trf) (Fig. 6). These data demonstrate that VL stimulation alters gene expression involved in glial differentiation, resulting in enhanced myelination and the potential for treatment or prevention of demyelinating diseases.
- Example 2 The brain cortices obtained from 88-week-old aged mice irradiated with violet light for 18 weeks in the same manner as in Example 1 were detected for myelin basic protein (MBP), a biomarker for mature oligodendrocytes, and DNA was stained. and stained with DAPI. The results are shown in FIGS. 8-10.
- VL indicates the results of mice in the experimental group irradiated with violet light.
- WL indicates the results of a control group of mice not irradiated with violet light.
- FIG. 9 shows the regions of brain cortex obtained.
- FIG. 10 is a graph comparing experimental group mice and control group mice with respect to MBP-expressing regions. The number of mice used in the experiment was 3 and 3-4 sites were examined for each mouse.
- Aged indicates 88 weeks of age and young indicates 13 weeks of age.
- Mean+SEM was One-way-ANOVA+post hoc (Tukey) with * ⁇ 0.05.
- rearing under violet light irradiation increases the area expressing MBP in the brain cortex and increases the number of mature oligodendrocytes in the brain cortex of aged mice. became clear.
- the method of the present invention can be applied to treat and/or prevent neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and recovery from spinal cord injury. I know you can.
- neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and recovery from spinal cord injury. I know you can.
- the method of the present invention can be applied to the treatment and/or prevention of brain tumors (glioma) and the like. Furthermore, it can be seen that the method of the present invention can be applied to treat and/or prevent pain, numbness, urinary incontinence, light-headedness, decreased vision, fatigue, etc. associated with myelination.
- Example 3 Eight-week-old young mice were irradiated with violet light for a short period of one week in the same manner as in Example 1, and oligodendrocyte biomarkers SOX10, CNP, and MAG were analyzed using brain hippocampal tissue. , MBP, Mobp and Myrf gene expression was confirmed by quantitative PCR.
- C57BL/6j mice were used. Mice in the experimental group, numbered 4, were exposed to violet light daily from 10:00 am to 12:00 am. Mice in the control group, numbered 4, were housed under white light (WL) from 8:00 am to 8:00 pm with a 12 h light/12 h dark cycle. The results are shown in FIG. In FIG. 11, VL indicates the results of mice in the experimental group irradiated with violet light.
- WL indicates the results of a control group of mice not irradiated with violet light.
- FIG. 11 in mice of the experimental group, gene expression of SOX10, CNP, MAG, MBP, Mobp and Myrf was increased in hippocampal tissue of the brain compared to mice of the control group.
- short-term violet light is sufficient to activate and induce differentiation of oligodendrocytes in a young state. From this, it can be seen that the method of the present invention can be applied to the treatment and/or prevention of various central nervous system diseases, brain tumors, etc., and to the improvement of healthcare.
- Example 4 Experimental animals (C57Bl6/J) in which depression was induced in the Social Defeat Stress model were irradiated with violet light for 10 days in the same manner as in Example 1.
- Nucleus Accumbens The expression of c-Fos, MBP, CC1 and Iba1 in the nucleus accumbens) was confirmed. The results are shown in Figures 12-14.
- Violet Light indicates the results of mice in the experimental group irradiated with violet light.
- WL indicates the results of a control group of mice not irradiated with violet light.
- stress indicates that depression was induced.
- Non stress indicates that depression is not induced.
- Figure 13 shows the Nucleus Accumbens region of the brain.
- FIG. 12 shows the Nucleus Accumbens region of the brain.
- FIG. 14 is a graph quantifying the results of the photographs of FIG.
- WL indicates the results of a control group of mice not irradiated with violet light.
- cVL indicates the results for the experimental group of mice irradiated with violet light.
- stress indicates whether depression was induced.
- CC1 and MBP which are mature oligodendrocyte makers, increased in the brain Nucleus Accumbens (nucleus accumbens).
- the method of the present invention can be applied to treat and/or prevent neurodegenerative diseases and tumors, and can be applied to improve health care.
- Example 5 The same experiment as in Example 4 was performed, except that the brain site was replaced with the Prefrontal cortex instead of the Nucleus Accumbens (nucleus accumbens). The results are shown in Figures 15-17.
- FIG. 16 shows regions of the Prefrontal cortex of the brain. As shown in Figures 15 and 17, in the experimental group of mice irradiated with violet light, CC1 and MBP, which are mature oligodendrocyte makers, increased in the prefrontal cortex of the brain, and nerves were activated. Activated (c-Fos) and increased microglia, immune cells in the brain (Iba1).
- CC1 and MBP which are mature oligodendrocyte makers
- violet light restores oligodendrocytes and microglia, which are reduced by stress, and activates nerves and immunity. Therefore, it can be seen that the method of the present invention can be applied to treat and/or prevent neurodegenerative diseases and tumors, and can be applied to improve health care.
- Example 6 In the Social Defeat Stress model, experimental animals (C57Bl6/J) that did not induce depression and mice that induced depression were irradiated with violet light for 10 days in the same manner as in Example 1. bottom. Gene expression of Fibroblast growth factor (FGF) was confirmed in the prefrontal cortex of the brain. FGF1 and FGF22 are known to be important factors in oligodendrocyte differentiation and myelination. The results are shown in Figures 18-19. In Figures 18 and 19, WL indicates the results of the control group of mice not irradiated with violet light. cVL indicates the results for the experimental group of mice irradiated with violet light. stress indicates whether depression was induced by the Social Defeat Stress model. As shown in FIGS.
- Example 7 Young mice (C57BL/6j) aged 8 weeks to 10 weeks were irradiated with violet light (normal light) for 4 weeks in the same manner as in Example 3, and the expression of FGF21 mRNA in the hippocampus of the left brain and right brain was confirmed.
- the results are shown in FIG. WL indicates a control group irradiated with white light of 50 lux from 8:00 to 20:00.
- VL indicates an experimental group that was irradiated with violet light from 8:00 to 11:00 in addition to being irradiated with white light of 50 lux from 8:00 to 20:00.
- the WL population is 4 and the VL population is 4.
- FGF21 expression was induced in the hippocampus of the right brain.
- FGF21 is known to induce oligodendrocyte differentiation. FGF21 has also been reported to improve cognitive function in the brain. From this, it can be seen that the method of the present invention can be applied to induce oligodendrocyte differentiation and improve brain cognitive function.
- Example 8 Example 1 to Example 7 are the same except that the violet light is emitted at a blinking frequency of 40 Hz instead of the violet light being emitted at a constant light (blinking frequency of 0 Hz).
- Example 9 Using the P301S mutant human tau transgenic mice (PS19) as an Alzheimer's disease model animal, experiments similar to those in these examples were performed except that they were irradiated with violet light at 40 Hz. It was confirmed. The results are shown in FIG. 40 Hz VL in FIG. 21 indicates the experimental group irradiated with 40 Hz violet light. cWL indicates the control group. As shown in FIG. 21, 40 Hz violet light irradiation increased the expression of the myelinating gene MAG (Myelin Associated Glycoprotein). This indicates that 40 Hz violet light irradiation promotes differentiation of oligodendrocytes.
- MAG Myelin Associated Glycoprotein
- Appendix 1 A method for treating and/or preventing a disease in a subject in need of treatment and/or prevention, said method comprising irradiating a subject with light of a specific wavelength, wherein said disease is a demyelinating disease , neurodegenerative diseases, tumors, central nervous system diseases and conditions associated with myelination.
- Appendix 2 said method comprising irradiating a subject with light of a specific wavelength to promote regeneration or increase of myelin in at least one region of the subject's central nervous system to treat and/or prevent a disease in said subject; 2.
- the disease is selected from the group consisting of demyelinating diseases, neurodegenerative diseases, tumors, central nervous system diseases and conditions associated with myelination.
- Appendix 3 A method for treating and/or preventing a disease in a subject in need of treatment and/or prevention, the method comprising controlling a light irradiation device to irradiate a subject with light of a specific wavelength, thereby , promoting the regeneration or increase of myelin in at least one region of the central nervous system of the subject to treat and/or prevent a disease in the subject, wherein the disease is a demyelinating disease, a neurodegenerative disease, a tumor, A method selected from the group consisting of central nervous system disorders and conditions associated with myelination.
- Appendix 4 The method according to appendix 3, wherein the light irradiation device includes a light source that irradiates the living body with light of a specific wavelength at a constant light or a specific blinking frequency, and a controller that controls the blinking frequency of the light source.
- Demyelinating diseases include multiple sclerosis, neuromyelitis optica (Devic syndrome), concentric sclerosis (Balo disease), acute disseminated encephalomyelitis (ADEM), inflammatory diffuse sclerosis (Schilder disease), subacute sclerosis panencephalitis (SSPE), progressive multifocal leukoencephalopathy (PML), hypoxic encephalopathy, central pontine myelination, vitamin B12 deficiency, Guillain-Barré syndrome and Binswanger disease, Appendix 1- 5. The method of any one of 4. (Appendix 6) 6.
- the neurodegenerative disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), Alzheimer's disease and spinal cord injury.
- ALS amyotrophic lateral sclerosis
- Appendix 7 The method of any one of appendices 1-6, wherein the tumor is a brain tumor (glioma).
- Appendix 8) 8. The method of any one of Appendices 1-7, wherein the central nervous system disease is cerebral infarction.
- Appendix 9) 9. The method of any one of appendices 1-8, wherein the symptoms associated with myelination are selected from the group consisting of pain, numbness, urinary incontinence, light-headedness, decreased vision and fatigue.
- Appendix 10 A method for promoting the regeneration or increase of myelin in at least one region of the central nervous system in a subject in need of treatment and/or prevention, the method comprising irradiating the subject with a specific wavelength of light. , promoting the regeneration or increase of myelin in at least one region of the subject's central nervous system.
- a method for promoting survival, proliferation or differentiation of oligodendrocyte progenitor cells or oligodendrocytes in at least one region of the central nervous system in a subject in need of treatment and/or prevention comprising: A method comprising irradiating a subject with light of a specific wavelength to promote survival, proliferation or differentiation of oligodendrocyte progenitor cells or oligodendrocytes in at least one region of the central nervous system of the subject.
- Appendix 12 The subject is receiving or has received at least one agent selected from the group consisting of steroids, glatiramer acetate, fingolimod hydrochloride, siponimod fumarate, dimethyl fumarate, interferon beta, natalizumab, and ofatumumab 12.
- Appendix 13 Any one of Appendices 1 to 12, which increases expression of at least one gene selected from the group consisting of Sox10, Cnp, Mag, Mbp, Mobp, Myrf, Pou3f1 and Trf in at least one region of the central nervous system described method.
- Appendix 14 14. The method of any one of clauses 1-13, wherein the light is violet light.
- Appendix 21 21.
- Method. (Appendix 22) 22 The method of any one of Appendices 1-21, wherein the subject is a human.
- (Appendix 23) at least one light source that emits light; a driving circuit for driving the light source; has The light emitted by the light source is light of a specific wavelength that produces therapeutic and/or preventive effects for diseases by irradiating the living body.
- a device for treatment and/or prevention of disease by light stimulation The device, wherein said disease is selected from the group consisting of demyelinating diseases, neurodegenerative diseases, tumors, central nervous system diseases and conditions associated with myelination.
- (Appendix 24) at least one light source that emits light; a driving circuit for driving the light source; has The light emitted by the light source is light of a specific wavelength that causes the effect of promoting the regeneration or increase of myelin by irradiating the living body.
- a device for promoting the regeneration or increase of myelin by photostimulation at least one light source that emits light; a driving circuit for driving the light source; has The light emitted by the light source is light of a specific wavelength that promotes the survival, proliferation, or differentiation of oligodendrocyte progenitor cells or oligodendrocytes by irradiating the living body.
- the drive circuit at least one processor communicatively connected to the light source and at least one memory; and at least one memory for storing processor-executable instructions.
- Appendix 27 The method of operating the device according to any one of Appendices 23 to 26, wherein the device controls a light source that irradiates a living body with light of a specific wavelength at a constant light or a specific blinking frequency, and the blinking frequency of the light source. wherein the control unit controls the blinking frequency of the light source in the range of 0 Hz or 30 to 75 Hz, and the light source irradiates the living body with light having a wavelength in the range of 350 to 400 nm. including, how it works.
- Appendix 28 A computer program for causing a device comprising a light source for irradiating a living body with light of a specific wavelength at a constant light or at a specific flickering frequency and a controller for controlling the flickering frequency of the light source to execute the operation method according to appendix 27.
- Appendix 29 At least one gene selected from the group consisting of Sox10, Cnp, Mag, Mbp, Mobp, Myrf, Pou3f1 and Trf in at least one region of the central nervous system of the subject by irradiating the subject with light of a specific wavelength Methods for increasing expression.
- (Appendix 30) A method for treating and/or preventing a demyelinating disease in a subject in need of treatment and/or prevention, the method comprising irradiating the subject with light of a specific wavelength and administering steroids, glatiramer to the subject A method comprising administering at least one agent selected from the group consisting of acetate, fingolimod hydrochloride, siponimod fumarate, dimethyl fumarate, interferon beta, natalizumab, and ofatumumab.
- (Appendix 31) at least one light source that emits light; a driving circuit for driving the light source; has the driving circuitry includes at least one processor communicatively connected to a light source and at least one memory; and at least one memory for storing processor-executable instructions;
- the light source is configured to emit light of a specific wavelength that causes treatment and/or prevention of disease by irradiating the living body.
- a device for treatment and/or prevention of disease by light stimulation The device, wherein said disease is selected from the group consisting of demyelinating diseases, neurodegenerative diseases, tumors, central nervous system diseases and conditions associated with myelination.
- (Appendix 32) at least one light source that emits light; a driving circuit for driving the light source; has the driving circuitry includes at least one processor communicatively connected to a light source and at least one memory; and at least one memory for storing processor-executable instructions; wherein the light source is configured to emit light of a specific wavelength that irradiates a living body to produce an effect of promoting the regeneration or increase of myelin; A device for promoting the regeneration or increase of myelin by photostimulation.
- (Appendix 33) at least one light source that emits light; a driving circuit for driving the light source; has the driving circuitry includes at least one processor communicatively connected to a light source and at least one memory; and at least one memory for storing processor-executable instructions; wherein the light source is configured to emit light of a specific wavelength that irradiates a living body to produce an effect of promoting the survival, proliferation or differentiation of oligodendrocyte progenitor cells or oligodendrocytes; A device for promoting the survival, proliferation or differentiation of oligodendrocyte progenitor cells or oligodendrocytes by photostimulation.
- a device for the treatment and/or prevention of a disease by photo-stimulation comprising a glass, spectacle lens or contact lens that allows violet light to pass through, wherein the disease is demyelinating disease, neurodegenerative disease, tumor, central nervous system disease and myelin A device selected from the group consisting of symptoms associated with formation.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本開示に係る疾患を治療及び/又は予防するための方法は、治療及び/又は予防を必要とする対象に特定波長の光を照射することを含むことを特徴とする。
本開示の1つの側面は、光刺激による前記疾患の治療及び/又は予防用装置に関する。いくつかの態様において、本開示に係る前記疾患の治療及び/又は予防用装置は、光を発する少なくとも1つの光源と、前記光源を駆動する駆動回路と、を有するものでありうる。ここで、前記光源が発する光は、生体へ照射することによって疾患の治療及び/又は予防効果を生じさせる特定波長の光である。
光源が発光する光の波長は特に限定されないが、一部の実施形態では360~400nmで定義されるバイオレットライトが使用される。
制御部は、光源からの光の照射状態(常灯や点滅周波数)をコントロールする部分である。制御部は、光源に電力を供給するための電源を備えたものであってもよく、そうした電源はバッテリーであってもよいし、別の位置に装着したバッテリーまでケーブルで引き回したものであってもよい。また、一箇所で動かない場合には、家庭用電源等に接続する形態であってもよい。
(マウスへの光照射)
ボックスの上部にLED(白:NF2W757GT-F1、紫:NSSU123、日亜化学工業、徳島)が取り付けられた光曝露装置(ニューオプト、神奈川、日本)中にマウスのケージを配置した。対照群のマウスは、12時間の明期/12時間の暗期のサイクルで午前8時から午後8時まで白色光(WL)の下で飼育した。実験群のマウスも、バイオレットライト(VL)への曝露を除いて、同じ条件下で白色光に曝露させた。実験群では、マウスを16週間、毎日午前10時から午前12時までバイオレットライトに曝露させた。バイオレットライトは360~400nmの波長光(ピーク波長375nm)を用い、放射照度で0.5~1000μW/cm2の範囲内、常灯(0Hzの点滅周波数)で照射した。
16週間の光照射を行った後、85週齢の老齢マウスを頸椎脱臼により屠殺し、各マウスの脳全体を採取した。組織を半分に分け、半分は免疫染色に使用し、残りの半分を遺伝子発現分析に使用した。すべての組織を液体窒素で急速凍結し、分析するまで-80℃で保存した。
海馬組織をQIAzol溶解試薬(Qiagen、ドイツ)でホモジナイズし、RNeasyミニキット(Qiagen、ドイツ)を使用してトータルRNAを抽出した。すべてのRNAサンプルの質と量をNanodrop RNA Nanoキット(2100 Agilent Bioanalyzer Technologies、CA、USA)を用いて決定した。遺伝子発現解析には、RIN(RNA integrity number)が8.0を超えるサンプルのみを使用した。
上記のように、QIAzol溶解試薬(Qiagen、ドイツ)で各組織からトータルRNAを単離し、Nanodrop Onec(Thermo Scientific)で濃度を測定した。逆転写酵素RNAキット(アプライドバイオシステムズ、日本)によるcDNA合成には500ngのトータルRNAを使用した。定量的リアルタイムPCRは、過去の文献に記載されているプロトコルに従って実行した。簡単に説明すると、SYBR Greenを使用したPCR反応を、Quant studio 5を使用して次の条件下で実施した:50℃で2分間、続いて95℃で10秒間および60℃で1分間を40サイクル。各転写物の値は、全ての実験条件で2つのサンプルの平均として計算した。値はGAPDHを内部対照として正規化した。データは、異なる群のサイクル閾値(Ct)を2-ΔΔCt法で比較して分析した。
脳の遺伝子発現プロファイルに対するバイオレットライト(VL)刺激の影響を評価するために、老齢マウスをVLに曝露した後、海馬についてRNA-seq解析を行った。その結果、231個のアップレギュレーションされた遺伝子と173個のダウンレギュレーションされた遺伝子を含む404個のDEG(差次的に発現する遺伝子)が同定された。遺伝子オントロジー(GO)分析を行い、DEGをアップレギュレートされた遺伝子とダウンレギュレートされた遺伝子に分類した結果、VL刺激が、ニューロンの被覆、軸索被覆、およびミエリン形成などの神経回路形成に関与する遺伝子の発現を増加させることが明らかとなった。グリア細胞の発達、特にオリゴデンドロサイトの分化が、アップレギュレートされた遺伝子のクラスターに含まれていることは注目に値する。このように、VLに曝露された老齢マウスは、オリゴデンドロサイトの分化に関連する遺伝子のアップレギュレーションを示す。具体的には、VLによりアップレギュレートされた遺伝子は、プレオリゴデンドロサイト(pre-OL)から成熟オリゴデンドロサイトへの分化に重要な役割を果たすが、これには、Sox10、Cnp、Mag、Mbp、Mobpなどのミエリン成熟に関与する遺伝子が含まれている(図6及び7)。さらに、VLは、オリゴデンドロサイト分化遺伝子を誘導する既知のSox10補因子であるMyrfの発現を増加させた。VLは、Pou3f1やトランスフェリン(Trf)などの他のオリゴデンドロサイト関連遺伝子も誘導する(図6)。これらのデータは、VL刺激がグリア分化に関与する遺伝子発現を変更させることを示しており、その結果としてミエリン形成が促進され、脱髄疾患の治療又は予防が可能であることを示している。
実施例1と同様に18週間バイオレットライトを照射した88週齢の老齢マウスから得た脳皮質について、成熟したオリゴデンドロサイトのバイオマーカーであるMBP(myelin basic protein)を検出するとともに、DNAを染色するDAPIで染色した。
結果を図8~図10に示す。図8において、VLは、バイオレットライトを照射した実験群のマウスの結果を示す。WLは、バイオレットライトを照射しない対照群のマウスの結果を示す。図9は、得た脳皮質の部位を示す。図10は、MBPが発現する領域について実験群のマウスと対照群のマウスを対比したグラフである。実験に用いたマウスの数は、3であり、それぞれのマウスにつき3~4の部位を検討した。図10において、Agedは88週齢を示し、youngは13週齢を示す。Mean+SEMは、One-way-ANOVA +post hoc (Tukey)で、* <0.05であった。
図8及び図10に示すように、バイオレットライト照射の環境下で飼育することで、脳皮質においてMBPが発現する領域が増大し、成熟したオリゴデンドロサイトが老齢のマウスにおける脳皮質で増加することが明らかとなった。このことから、本発明の方法は、アルツハイマー病、多発性硬化症、筋萎縮性側索硬化症(ALS)、脊椎損傷からの回復などの神経変性疾患の治療及び/又は予防に応用することができることが分かる。また、本発明の方法は、脳腫瘍(グリオーマ)などの治療及び/又は予防に応用することができることが分かる。さらに、本発明の方法は、ミエリン形成に付随する疼痛、痺れ、尿漏れ、ふらつき、視力低下、疲れ、などの治療及び/又は予防に応用することができることが分かる。
8週齢の若いマウスに対して、1週間の短期間のバイオレットライトを実施例1と同様に照射し、脳の海馬の組織を用いて、オリゴデンドロサイトのバイオマーカーであるSOX10、CNP、MAG、MBP、Mobp及びMyrfの遺伝子発現を、定量PCRによって確認した。マウスは、C57BL/6jを用いた。実験群のマウスは、個体数が4であり、毎日午前10時から午前12時までバイオレットライトに曝露させた。対照群のマウスは、個体数が4であり、12時間の明期/12時間の暗期のサイクルで午前8時から午後8時まで白色光(WL)の下で飼育した。
結果を図11に示す。図11において、VLは、バイオレットライトを照射した実験群のマウスの結果を示す。WLは、バイオレットライトを照射しない対照群のマウスの結果を示す。
図11に示すように、実験群のマウスにおいては、対照群のマウスに比べて、脳の海馬の組織におけるSOX10、CNP、MAG、MBP、Mobp及びMyrfの遺伝子発現が増大していた。このように、若い状態で、短期的なバイオレットライトで十分、オリゴデンドロサイトを活性化、分化誘導することができることが明らかとなった。このことから、本発明の方法は、さまざまな中枢神経疾患や脳腫瘍などの治療及び/又は予防や、ヘルスケア向上に応用することができることが分かる。
Social Defeat Stress model (社会的敗北ストレスモデル)にて、うつ病を誘導した実験動物(C57Bl6/J)に対して、実施例1と同様にバイオレットライトを10日間照射した後、脳のNucleus Accumbens (側坐核)におけるc-Fos、MBP、CC1及びIba1の発現を確認した。
結果を図12~図14に示す。図12において、Violet Lightは、バイオレットライトを照射した実験群のマウスの結果を示す。WLは、バイオレットライトを照射しない対照群のマウスの結果を示す。図12において、stressは、うつ病を誘導したことを示す。non stressは、うつ病の誘導をしていないことを示す。図13は、脳のNucleus Accumbens (側坐核)の部位を示す。図14は、図12の写真の結果を定量化したグラフである。図14において、WLは、バイオレットライトを照射しない対照群のマウスの結果を示す。cVLは、バイオレットライトを照射した実験群のマウスの結果を示す。stressは、うつ病を誘導したかどうかを示す。
図12及び図14に示すように、バイオレットライトを照射した実験群のマウスにおいては、脳のNucleus Accumbens (側坐核)にて、成熟オリゴデンドロサイトmakerであるCC1及びMBPが増加し、神経が活性化(c-Fos)しており、脳の免疫細胞であるミクログリアが増加していた(Iba1)。このことから、バイオレットライトは、ストレスで減少するオリゴデンドロサイトを回復させて、神経や免疫を活性化させることが明らかとなった。したがって、本発明の方法は、神経変性疾患や腫瘍の治療及び/又は予防に応用することができ、ヘルスケア向上に応用することができることが分かる。
脳の部位を、Nucleus Accumbens (側坐核)に代えてPrefrontal cortex (前頭前皮質)としたほかは、実施例4と同様の実験を行った。
結果を図15~図17に示す。図16は、脳のPrefrontal cortex (前頭前皮質)の部位を示す。
図15及び図17に示すように、バイオレットライトを照射した実験群のマウスにおいては、脳のPrefrontal cortex (前頭前皮質)にて、成熟オリゴデンドロサイトmakerであるCC1及びMBPが増加し、神経が活性化(c-Fos)しており、脳の免疫細胞であるミクログリアが増加していた(Iba1)。このことから、バイオレットライトは、ストレスで減少するオリゴデンドロサイト及びマイクログリアを回復させて、神経や免疫を活性化させることが明らかとなった。したがって、本発明の方法は、神経変性疾患や腫瘍の治療及び/又は予防に応用することができ、ヘルスケア向上に応用することができることが分かる。
Social Defeat Stress model (社会的敗北ストレスモデル)にて、うつ病を誘導しなかった実験動物(C57Bl6/J)とうつ病を誘導したマウスにて、実施例1と同様にバイオレットライトを10日間照射した。脳のPrefrontal cortex (前頭前皮質)にて、Fibroblast growth factor(FGF)の遺伝子発現を確認した。FGF1及びFGF22は、オリゴデンドロサイトの分化とミエリン形成に重要な因子として知られている。
結果を図18~図19に示す。図18及び図19において、WLは、バイオレットライトを照射しない対照群のマウスの結果を示す。cVLは、バイオレットライトを照射した実験群のマウスの結果を示す。stressは、Social Defeat Stress model (社会的敗北ストレスモデル)によってうつ病を誘導したかどうかを示す。
図18及び図19に示すように、10日間のバイオレットライト照射にて、FGF1及びFGF22の遺伝子発現が脳のPrefrontal cortex (前頭前皮質)で増加することが明らかとなった。FGF1やFGF22は、細胞の増殖、修復、炎症抑制などに広く関与しているため、本発明の方法は、様々な用途に用いることができることが分かる。
実施例3と同様に8週齢から10週齢の若いマウス(C57BL/6j)にバイオレットライト(常灯)を4週間照射して、左脳及び右脳の海馬におけるFGF21 mRNAの発現を確認した。
結果を図20に示す。WLは、50luxの白色光を8時から20時まで照射した対照群を示す。VLは、50luxの白色光を8時から20時まで照射することに加えて8時から11時までバイオレットライトを照射した実験群を示す。WLの個体数は、4であり、VLの個体数は、4である。
図20に示すように、FGF21の発現は、右脳の海馬において誘導されていた。FGF21は、オリゴデンドロサイトの分化を誘導することが知られている。また、FGF21は、脳で認知機能を改善することも報告されている。このことから、本発明の方法は、オリゴデンドロサイトの分化を誘導し、脳の認知機能の改善に応用することができることが分かる。
バイオレットライトを常灯(0Hzの点滅周波数)で照射することに代えて、バイオレットライトを40Hzの点滅周波数で照射するほかは、実施例1~実施例7と同様とする。
P301S変異ヒトタウ遺伝子導入マウス(PS19)のアルツハイマー病モデル動物を用いて、40Hzバイオレットライトを照射したほかは、これらの実施例と同様の実験を行い、ミエリン形成遺伝子のMAG (Myelin Associated Glycoprotein)の発現を確認した。
結果を図21に示す。図21において40Hz VLは、40Hzバイオレットライトを照射した実験群を示す。cWLは、対照群を示す。
図21に示すように、40Hzバイオレットライトの照射により、ミエリン形成遺伝子のMAG (Myelin Associated Glycoprotein)の発現が増加していた。このことから、40Hzのバイオレットライトの照射が、オリゴデンドロサイトの分化を促進することが分かる。
治療及び/又は予防を必要とする対象において疾患を治療及び/又は予防するための方法であって、該方法が、対象に特定波長の光を照射することを含み、前記疾患が、脱髄疾患、神経変性疾患、腫瘍、中枢神経疾患及びミエリン形成に付随する症状からなる群から選ばれる、方法。
(付記2)
前記方法が、対象に特定波長の光を照射して、対象の中枢神経系の少なくとも1つの領域におけるミエリンの再生又は増加を促進し、対象における疾患を治療及び/又は予防することを含み、前記疾患が、脱髄疾患、神経変性疾患、腫瘍、中枢神経疾患及びミエリン形成に付随する症状からなる群から選ばれる、付記1に記載の方法。
(付記3)
治療及び/又は予防を必要とする対象において疾患を治療及び/又は予防するための方法であって、該方法が、光照射装置を制御して、特定波長の光を対象に照射し、それにより、対象の中枢神経系の少なくとも1つの領域におけるミエリンの再生又は増加を促進して、対象における疾患を治療及び/又は予防することを含み、前記疾患が、脱髄疾患、神経変性疾患、腫瘍、中枢神経疾患及びミエリン形成に付随する症状からなる群から選ばれる、方法。
(付記4)
前記光照射装置は、特定波長の光を常灯又は特定の点滅周波数で生体に照射する光源と、前記光源の点滅周波数を制御する制御部とを備える、付記3に記載の方法。
(付記5)
脱髄疾患が、多発性硬化症、視神経脊髄炎(Devic症候群)、同心円硬化症(Balo病)、急性散在性脳脊髄炎(ADEM)、炎症性広汎性硬化症(Schilder病)、亜急性硬化症全脳炎(SSPE)、進行性多巣性白質脳症(PML)、低酸素脳症、橋中心髄鞘破壊症、ビタミンB12欠乏症、ギランバレー症候群及びBinswanger病から成る群から選択される、付記1~4のいずれか1項記載の方法。
(付記6)
神経変性疾患が、筋萎縮性側索硬化症(ALS)、アルツハイマー病及び脊椎損傷から成る群から選択される、付記1~5のいずれか1項記載の方法。
(付記7)
腫瘍が脳腫瘍(グリオーマ)である、付記1~6のいずれか1項記載の方法。
(付記8)
中枢神経疾患が脳梗塞である、付記1~7のいずれか1項記載の方法。
(付記9)
ミエリン形成に付随する症状が、疼痛、痺れ、尿漏れ、ふらつき、視力低下及び疲れから成る群から選択される、付記1~8のいずれか1項記載の方法。
(付記10)
治療及び/又は予防を必要とする対象において、中枢神経系の少なくとも1つの領域におけるミエリンの再生又は増加を促進するための方法であって、該方法が、対象に特定波長の光を照射して、対象の中枢神経系の少なくとも1つの領域におけるミエリンの再生又は増加を促進することを含む、方法。
(付記11)
治療及び/又は予防を必要とする対象において、中枢神経系の少なくとも1つの領域におけるオリゴデンドロサイト前駆細胞又はオリゴデンドロサイトの生存、増殖又は分化を促進するための方法であって、該方法が、対象に特定波長の光を照射して、対象の中枢神経系の少なくとも1つの領域におけるオリゴデンドロサイト前駆細胞又はオリゴデンドロサイトの生存、増殖又は分化を促進することを含む、方法。
(付記12)
対象が、ステロイド、グラチラマー酢酸塩、フィンゴリモド塩酸塩、シポニモドフマル酸、フマル酸ジメチル、インターフェロンβ、ナタリズマブ、及びオファツムマブから成る群より選択される少なくとも1つの薬剤の投与を受けているか、又は受けたことがある、付記1~11のいずれか1項記載の方法。
(付記13)
中枢神経系の少なくとも1つの領域においてSox10、Cnp、Mag、Mbp、Mobp、Myrf、Pou3f1及びTrfから成る群から選択される少なくとも1つの遺伝子の発現を増加させる、付記1~12のいずれか1項記載の方法。
(付記14)
前記光はバイオレットライトである、付記1~13のいずれか1項記載の方法。
(付記15)
前記特定波長は350~400nmを含む、付記1~14のいずれか1項記載の方法。
(付記16)
前記特定波長は約380nmを含む、付記15記載の方法。
(付記17)
点滅周波数は0Hz又は30~70Hzである、付記1~16のいずれか1項記載の方法。
(付記18)
前記点滅周波数は0Hz又は35~60Hzである、付記17記載の方法。
(付記19)
前記点滅周波数は0Hz又は約40Hzである、付記18記載の方法。
(付記20)
照射条件は、前記光源の照射時間をさらに含む、付記1~19のいずれか1項記載の方法。
(付記21)
光源は、光源付きめがね若しくはめがねフレーム、卓上光源、移動体端末装着光源、顔前又は近傍設置型光源、携帯光源、室内照明、又は卓上スタンドである、付記1~20のいずれか1項記載の方法。
(付記22)
対象がヒトである、付記1~21のいずれか1項記載の方法。
(付記23)
光を発する少なくとも1つの光源と、
前記光源を駆動する駆動回路と、
を有し、
前記光源が発する光は、生体へ照射することによって疾患の治療及び/又は予防効果を生じさせる特定波長の光である、
光刺激による疾患の治療及び/又は予防用装置であって、
前記疾患が、脱髄疾患、神経変性疾患、腫瘍、中枢神経疾患及びミエリン形成に付随する症状からなる群から選ばれる、装置。
(付記24)
光を発する少なくとも1つの光源と、
前記光源を駆動する駆動回路と、
を有し、
前記光源が発する光は、生体へ照射することによってミエリンの再生又は増加を促進する効果を生じさせる特定波長の光である、
光刺激によるミエリンの再生又は増加促進用装置。
(付記25)
光を発する少なくとも1つの光源と、
前記光源を駆動する駆動回路と、
を有し、
前記光源が発する光は、生体へ照射することによってオリゴデンドロサイト前駆細胞又はオリゴデンドロサイトの生存、増殖又は分化を促進する効果を生じさせる特定波長の光である、
光刺激によるオリゴデンドロサイト前駆細胞又はオリゴデンドロサイトの生存、増殖又は分化を促進する装置。
(付記26)
前記駆動回路が、
光源及び少なくとも1つのメモリに通信可能に接続された少なくとも1つのプロセッサと、
プロセッサが実行可能な命令を格納するための少なくとも1つのメモリ
とを含む、付記23~25のいずれか1項記載の装置。
(付記27)
付記23~26のいずれか1項記載の装置の作動方法であって、前記装置は、特定波長の光を常灯又は特定の点滅周波数で生体に照射する光源と、前記光源の点滅周波数を制御する制御部とを備え、前記制御部が、前記光源の点滅周波数を0Hz又は30~75Hzの範囲において制御する段階、前記光源が、350~400nmの範囲の波長の光を生体に照射する段階を含む、作動方法。
(付記28)
特定波長の光を常灯又は特定の点滅周波数で生体に照射する光源と、前記光源の点滅周波数を制御する制御部とを備えた装置に付記27に記載の作動方法を実行させるコンピュータプログラム。
(付記29)
対象に特定波長の光を照射することにより、対象の中枢神経系の少なくとも1つの領域におけるSox10、Cnp、Mag、Mbp、Mobp、Myrf、Pou3f1及びTrfから成る群から選択される少なくとも1つの遺伝子の発現を増加させる方法。
(付記30)
治療及び/又は予防を必要とする対象において脱髄疾患を治療及び/又は予防するための方法であって、該方法が、対象に特定波長の光を照射すること、並びに、対象にステロイド、グラチラマー酢酸塩、フィンゴリモド塩酸塩、シポニモドフマル酸、フマル酸ジメチル、インターフェロンβ、ナタリズマブ、及びオファツムマブから成る群より選択される少なくとも1つの薬剤を投与することを含む、方法。
(付記31)
光を発する少なくとも1つの光源と、
前記光源を駆動する駆動回路と、
を有し、
前記駆動回路は、光源及び少なくとも1つのメモリに通信可能に接続された少なくとも1つのプロセッサと、プロセッサが実行可能な命令を格納するための少なくとも1つのメモリとを含み、
前記光源が、生体へ照射することによって疾患の治療及び/又は予防効果を生じさせる特定波長の光を発するように構成されている、
光刺激による疾患の治療及び/又は予防用装置であって、
前記疾患が、脱髄疾患、神経変性疾患、腫瘍、中枢神経疾患及びミエリン形成に付随する症状からなる群から選ばれる、装置。
(付記32)
光を発する少なくとも1つの光源と、
前記光源を駆動する駆動回路と、
を有し、
前記駆動回路は、光源及び少なくとも1つのメモリに通信可能に接続された少なくとも1つのプロセッサと、プロセッサが実行可能な命令を格納するための少なくとも1つのメモリとを含み、
前記光源が、生体へ照射することによってミエリンの再生または増加を促進する効果を生じさせる特定波長の光を発するように構成されている、
光刺激によるミエリンの再生または増加促進用装置。
(付記33)
光を発する少なくとも1つの光源と、
前記光源を駆動する駆動回路と、
を有し、
前記駆動回路は、光源及び少なくとも1つのメモリに通信可能に接続された少なくとも1つのプロセッサと、プロセッサが実行可能な命令を格納するための少なくとも1つのメモリとを含み、
前記光源が、生体へ照射することによってオリゴデンドロサイト前駆細胞又はオリゴデンドロサイトの生存、増殖又は分化を促進する効果を生じさせる特定波長の光を発するように構成されている、
光刺激によるオリゴデンドロサイト前駆細胞又はオリゴデンドロサイトの生存、増殖又は分化を促進する装置。
(付記34)
命令が格納された非一時的(non-transitory)なコンピュータ可読媒体であって、命令がプロセッサによって実行されると、以下のステップを実行することができる、コンピュータ可読媒体:
特定波長の光を常灯又は特定の点滅周波数で生体に照射する光源と、前記光源の点滅周波数を制御する制御部とを備える装置に対して、
前記制御部が、前記光源の点滅周波数を0Hz又は30~75Hzの範囲において制御するように前記装置を作動させるステップ、並びに
前記光源が、350~400nmの範囲の波長の光を生体に照射するように前記装置を作動させるステップ。
(付記35)
バイオレットライトを通過させるガラス、めがねレンズ又はコンタクトレンズを含む、光刺激による疾患の治療及び/又は予防用器具であって、前記疾患が、脱髄疾患、神経変性疾患、腫瘍、中枢神経疾患及びミエリン形成に付随する症状からなる群から選ばれる、器具。
Claims (28)
- 治療及び/又は予防を必要とする対象において疾患を治療及び/又は予防するための方法であって、該方法が、対象に特定波長の光を照射することを含み、前記疾患が、脱髄疾患、神経変性疾患、腫瘍、中枢神経疾患及びミエリン形成に付随する症状からなる群から選ばれる、方法。
- 前記方法が、対象に特定波長の光を照射して、対象の中枢神経系の少なくとも1つの領域におけるミエリンの再生又は増加を促進し、対象における疾患を治療及び/又は予防することを含み、前記疾患が、脱髄疾患、神経変性疾患、腫瘍、中枢神経疾患及びミエリン形成に付随する症状からなる群から選ばれる、請求項1に記載の方法。
- 治療及び/又は予防を必要とする対象において疾患を治療及び/又は予防するための方法であって、該方法が、光照射装置を制御して、特定波長の光を対象に照射し、それにより、対象の中枢神経系の少なくとも1つの領域におけるミエリンの再生又は増加を促進して、対象における疾患を治療及び/又は予防することを含み、前記疾患が、脱髄疾患、神経変性疾患、腫瘍、中枢神経疾患及びミエリン形成に付随する症状からなる群から選ばれる、方法。
- 前記光照射装置は、特定波長の光を常灯又は特定の点滅周波数で生体に照射する光源と、前記光源の点滅周波数を制御する制御部とを備える、請求項3に記載の方法。
- 脱髄疾患が、多発性硬化症、視神経脊髄炎(Devic症候群)、同心円硬化症(Balo病)、急性散在性脳脊髄炎(ADEM)、炎症性広汎性硬化症(Schilder病)、亜急性硬化症全脳炎(SSPE)、進行性多巣性白質脳症(PML)、低酸素脳症、橋中心髄鞘破壊症、ビタミンB12欠乏症、ギランバレー症候群及びBinswanger病から成る群から選択される、請求項1~4のいずれか1項記載の方法。
- 神経変性疾患が、筋萎縮性側索硬化症(ALS)、アルツハイマー病及び脊椎損傷から成る群から選択される、請求項1~5のいずれか1項記載の方法。
- 腫瘍が脳腫瘍(グリオーマ)である、請求項1~6のいずれか1項記載の方法。
- 中枢神経疾患が脳梗塞である、請求項1~7のいずれか1項記載の方法。
- ミエリン形成に付随する症状が、疼痛、痺れ、尿漏れ、ふらつき、視力低下及び疲れから成る群から選択される、請求項1~8のいずれか1項記載の方法。
- 治療及び/又は予防を必要とする対象において、中枢神経系の少なくとも1つの領域におけるミエリンの再生又は増加を促進するための方法であって、該方法が、対象に特定波長の光を照射して、対象の中枢神経系の少なくとも1つの領域におけるミエリンの再生又は増加を促進することを含む、方法。
- 治療及び/又は予防を必要とする対象において、中枢神経系の少なくとも1つの領域におけるオリゴデンドロサイト前駆細胞又はオリゴデンドロサイトの生存、増殖又は分化を促進するための方法であって、該方法が、対象に特定波長の光を照射して、対象の中枢神経系の少なくとも1つの領域におけるオリゴデンドロサイト前駆細胞又はオリゴデンドロサイトの生存、増殖又は分化を促進することを含む、方法。
- 対象が、ステロイド、グラチラマー酢酸塩、フィンゴリモド塩酸塩、シポニモドフマル酸、フマル酸ジメチル、インターフェロンβ、ナタリズマブ、及びオファツムマブから成る群より選択される少なくとも1つの薬剤の投与を受けているか、又は受けたことがある、請求項1~11のいずれか1項記載の方法。
- 中枢神経系の少なくとも1つの領域においてSox10、Cnp、Mag、Mbp、Mobp、Myrf、Pou3f1及びTrfから成る群から選択される少なくとも1つの遺伝子の発現を増加させる、請求項1~12のいずれか1項記載の方法。
- 前記光はバイオレットライトである、請求項1~13のいずれか1項記載の方法。
- 前記特定波長は350~400nmを含む、請求項1~14のいずれか1項記載の方法。
- 前記特定波長は約380nmを含む、請求項15記載の方法。
- 点滅周波数は0Hz又は30~70Hzである、請求項1~16のいずれか1項記載の方法。
- 前記点滅周波数は0Hz又は35~60Hzである、請求項17記載の方法。
- 前記点滅周波数は0Hz又は約40Hzである、請求項18記載の方法。
- 照射条件は、前記光源の照射時間をさらに含む、請求項1~19のいずれか1項記載の方法。
- 光源は、光源付きめがね若しくはめがねフレーム、卓上光源、移動体端末装着光源、顔前又は近傍設置型光源、携帯光源、室内照明、又は卓上スタンドである、請求項1~20のいずれか1項記載の方法。
- 対象がヒトである、請求項1~21のいずれか1項記載の方法。
- 光を発する少なくとも1つの光源と、
前記光源を駆動する駆動回路と、
を有し、
前記光源が発する光は、生体へ照射することによって疾患の治療及び/又は予防効果を生じさせる特定波長の光である、
光刺激による疾患の治療及び/又は予防用装置であって、
前記疾患が、脱髄疾患、神経変性疾患、腫瘍、中枢神経疾患及びミエリン形成に付随する症状からなる群から選ばれる、装置。 - 光を発する少なくとも1つの光源と、
前記光源を駆動する駆動回路と、
を有し、
前記光源が発する光は、生体へ照射することによってミエリンの再生又は増加を促進する効果を生じさせる特定波長の光である、
光刺激によるミエリンの再生又は増加促進用装置。 - 光を発する少なくとも1つの光源と、
前記光源を駆動する駆動回路と、
を有し、
前記光源が発する光は、生体へ照射することによってオリゴデンドロサイト前駆細胞又はオリゴデンドロサイトの生存、増殖又は分化を促進する効果を生じさせる特定波長の光である、
光刺激によるオリゴデンドロサイト前駆細胞又はオリゴデンドロサイトの生存、増殖又は分化を促進する装置。 - 前記駆動回路が、
光源及び少なくとも1つのメモリに通信可能に接続された少なくとも1つのプロセッサと、
プロセッサが実行可能な命令を格納するための少なくとも1つのメモリ
とを含む、請求項23~25のいずれか1項記載の装置。 - 請求項23~26のいずれか1項記載の装置の作動方法であって、前記装置は、特定波長の光を常灯又は特定の点滅周波数で生体に照射する光源と、前記光源の点滅周波数を制御する制御部とを備え、前記制御部が、前記光源の点滅周波数を0Hz又は30~75Hzの範囲において制御する段階、前記光源が、350~400nmの範囲の波長の光を生体に照射する段階を含む、作動方法。
- 特定波長の光を常灯又は特定の点滅周波数で生体に照射する光源と、前記光源の点滅周波数を制御する制御部とを備えた装置に請求項27に記載の作動方法を実行させるコンピュータプログラム。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023556646A JPWO2023074813A1 (ja) | 2021-10-27 | 2022-10-27 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021175619 | 2021-10-27 | ||
JP2021-175619 | 2021-10-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023074813A1 true WO2023074813A1 (ja) | 2023-05-04 |
Family
ID=86160008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/040211 WO2023074813A1 (ja) | 2021-10-27 | 2022-10-27 | 光刺激による疾患の治療方法及びそれに用いる装置 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2023074813A1 (ja) |
TW (1) | TW202327694A (ja) |
WO (1) | WO2023074813A1 (ja) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015186723A1 (ja) | 2014-06-03 | 2015-12-10 | 株式会社 坪田ラボ | 近視予防物品 |
JP2017141175A (ja) * | 2016-02-09 | 2017-08-17 | 小野薬品工業株式会社 | 多発性硬化症の予防および/または治療剤 |
JP2020507414A (ja) * | 2017-02-15 | 2020-03-12 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 改善された光療法システムおよび使用方法 |
JP2021517501A (ja) * | 2018-03-09 | 2021-07-26 | ジョージア テック リサーチ コーポレイション | 脳シグナル伝達および遺伝子発現を制御するために神経活動を駆動するためのシステムおよび方法 |
-
2022
- 2022-10-27 WO PCT/JP2022/040211 patent/WO2023074813A1/ja active Application Filing
- 2022-10-27 JP JP2023556646A patent/JPWO2023074813A1/ja active Pending
- 2022-10-27 TW TW111140884A patent/TW202327694A/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015186723A1 (ja) | 2014-06-03 | 2015-12-10 | 株式会社 坪田ラボ | 近視予防物品 |
JP2017141175A (ja) * | 2016-02-09 | 2017-08-17 | 小野薬品工業株式会社 | 多発性硬化症の予防および/または治療剤 |
JP2020507414A (ja) * | 2017-02-15 | 2020-03-12 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 改善された光療法システムおよび使用方法 |
JP2021517501A (ja) * | 2018-03-09 | 2021-07-26 | ジョージア テック リサーチ コーポレイション | 脳シグナル伝達および遺伝子発現を制御するために神経活動を駆動するためのシステムおよび方法 |
Non-Patent Citations (13)
Title |
---|
AGING DIS., vol. 12, no. 8, 1 December 2021 (2021-12-01), pages 2096 - 2112 |
CELL REP, vol. 40, no. 8, 23 August 2022 (2022-08-23), pages 111239 |
EUR J NEUROSCI, vol. 53, no. 1, January 2021 (2021-01-01), pages 140 - 150 |
FRONT CELL NEUROSCI, vol. 14, 11 January 2021 (2021-01-11), pages 619707 |
FUJIYOSHI ET AL., J NEUROSCI, vol. 36, no. 9, 2 March 2016 (2016-03-02), pages 2796 - 808 |
HIDEMASA TORII ET AL., EBIOMEDICINE |
J CLIN INVEST, vol. 127, no. 9, 1 September 2017 (2017-09-01), pages 3496 - 3509 |
KAZUO TSUBOTA: "Blue Light Hazard", 20 November 2013, PUBLISHED BY SHUEISHA ON |
MEGUMI HATORIKAZUO TSUBOTA: "Japanese Society of Anti-aging Medicine Magazine", ANTI-AGING MEDICINE, vol. 11, no. 3, 2015, pages 065 |
NAT NEUROSCI, vol. 21, no. 5, May 2018 (2018-05-01), pages 683 - 695 |
NATURE COMMUNICATIONS, vol. 13, 2022, pages 1897 |
NATURE, vol. 465, no. 7299, 10 June 2010 (2010-06-10), pages 783 - 7 |
NEURON, vol. 109, no. 14, 21 July 2021 (2021-07-21), pages 2292 - 2307 |
Also Published As
Publication number | Publication date |
---|---|
TW202327694A (zh) | 2023-07-16 |
JPWO2023074813A1 (ja) | 2023-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Blume et al. | Effects of light on human circadian rhythms, sleep and mood | |
JP7458786B2 (ja) | 改善された光療法システムおよび使用方法 | |
Meesters et al. | Low-intensity blue-enriched white light (750 lux) and standard bright light (10 000 lux) are equally effective in treating SAD. A randomized controlled study | |
CN110913951B (zh) | 刺激视神经的***和方法 | |
JP5506677B2 (ja) | 概日リズムの変化を防止するための方法および機器 | |
US20080103561A1 (en) | Apparatus and Method for Providing a Multi-Stage Light Treatment | |
JP2014513614A (ja) | 脳内神経伝達物質レベルを変更する装置および方法 | |
JP6260953B2 (ja) | 認知症状やうつ様症状改善のための光照射装置、この光照射装置を備えた部屋、及び認知症状やうつ様症状改善のための照明器具 | |
WO2020027305A1 (ja) | 光刺激による脳波及び細胞活性制御装置及び方法、並びに脳機能を改善、予防又は増大する装置 | |
US20230084974A1 (en) | Light therapy system and methods of use | |
Vartanian et al. | Using flickering light to enhance nonimage-forming visual stimulation in humans | |
Timonen et al. | Can transcranial brain-targeted bright light treatment via ear canals be effective in relieving symptoms in seasonal affective disorder?–A pilot study | |
Chen | A theoretical approach for therapeutic artificial supplementary lighting in elderly living spaces | |
Zhu et al. | Repeated low-level red-light therapy for controlling onset and progression of myopia-a review | |
WO2023074813A1 (ja) | 光刺激による疾患の治療方法及びそれに用いる装置 | |
CN106994209B (zh) | 一种治疗抑郁发作的光源和光治疗设备 | |
JP7210060B2 (ja) | 脈絡膜の菲薄化抑制装置及びその作動方法 | |
WO2023153478A1 (ja) | 光刺激による生理状態の改善方法及びそれに用いる装置 | |
WO2024090566A1 (ja) | バイオレットライトによる網膜変性の進行抑制及び治療方法並びにそれに用いる装置 | |
RU2295989C2 (ru) | Способ регуляции физического и психоэмоционального статуса лиц, находящихся в состоянии десинхроноза | |
WO2022059757A1 (ja) | 脈絡膜の菲薄化抑制装置及び方法 | |
WO2022196798A1 (ja) | 光刺激による生体機能制御装置及びその作動方法 | |
WO2023141629A2 (en) | Methods, systems and devices for using green light for neurodegenerative diseases and other conditions | |
RU2319521C2 (ru) | Способ светового воздействия на физическое и психоэмоциональное состояние человека | |
Thankachan et al. | Low frequency visual stimulation enhances slow wave activity without disrupting the sleep pattern in mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22887138 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023556646 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022887138 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022887138 Country of ref document: EP Effective date: 20240527 |